Evaluation of TK3 in Improving Quality of Life in Patients With Malignancy Under Chemotherapy

Lavilabor Natural Products

Status and phase

Unknown

Phase 3

Conditions

Cancer

Treatments

Dietary Supplement: 1 capsule, 3 times per day

Dietary Supplement: TK3

Study type

Interventional

Funder types

Industry

Identifiers

NCT01168206

TK3a_FIII_Janeiro/2010

Details and patient eligibility

About

The association of nutritional supplement TK3 to conventional treatment of cancer patients reduces the intensity and frequency of toxic effects and side effects caused by adjuvant or palliative treatments for the protection of healthy tissues, resulting in a better quality of life.

Enrollment

80 estimated patients

Sex

All

Ages

30 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patient Consent: Informed Consent and informed consent signed and dated by the patient (or his legal representative) and the professional who has obtained the consent. Must be delivered before inclusion. This term must be read and explained to the patient.
Patients female or male, regardless of race or color.Able to ingest oral medication.
Patients 30-80 years, with malignancy, clinical stage III or IV on chemo or hormone therapy.
Patients who have a Karnofsky level between 60 and 80.

Exclusion criteria

no agreement to sign the Deed of Consent.
Need for use of parenteral nutrition.
The need for food supplement already approved.
Inability to receive the drug orally.
Participation in another clinical trial involving chemotherapy drugs.
Women being sexually active, which does not agree to adhere to the contraceptive methods adopted.
Women lactating
Any problem or condition that the investigator in the trial could be harmful to the patient.